QCG
BCAX

Quadrant Capital Group’s Bicara Therapeutics BCAX Stock Holding History

Quadrant Capital Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$259 Buy
+13
New +$224 ﹤0.01% 2654

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Quadrant Capital Group's BCAX Position: Q1 2026 in Review

Quadrant Capital Group opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 13 shares worth $259. The stake represents ﹤0.01% of the portfolio and ranks #2654 among its holdings.

146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Quadrant Capital Group held 13 shares of Bicara Therapeutics worth $259 as of Q1 2026.
  • Bicara Therapeutics was a new Quadrant Capital Group position in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2654 holding.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.